Is FATE or FDMT more undervalued in 2026?

CirclFi compares Fate Therapeutics, Inc. (FATE) and 4D Molecular Therapeutics, Inc. (FDMT) using 13 institutional-grade valuation models. FATE has a Quality of Company score of 5.5/10 while FDMT scores 7.1/10.

Which is a better buy — FATE or FDMT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do FATE and FDMT valuations compare?

FATE at $2.63 and FDMT at $8.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

FATE vs FDMT Valuation Comparison 2026 — Intrinsic Value Analysis

FATE

Biotechnology

Fate Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

SAFE

Price

$2.63

Last close

Models

9/13

Active

FDMT

Biotechnology

4D Molecular Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$8.97

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	FATE Fair Value	FATE Upside	FDMT Fair Value	FDMT Upside
Bayesian DCF	Intrinsic	$0.62	-76.3%	$3.01	-66.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.18	-88.1%	$4.34	-50.0%
Dynamic NAV	Asset-Based	$2.75	+4.7%	$8.24	-8.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for FATE vs FDMT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FATE vs FDMT — Which Stock Is More Undervalued?

FDMT scores higher with a 7.1/10 quality rating vs FATE's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Fate Therapeutics, Inc. (FATE) and 4D Molecular Therapeutics, Inc. (FDMT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FATE currently trades at $2.63 with a QOC of 5.5/10, while FDMT trades at $8.97 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).